Filing Analysis
Sangamo Therapeutics, Inc. has entered into an asset purchase agreement with PTC Therapeutics, Inc. as part of its Chapter 11 bankruptcy proceedings. The agreement involves the sale of assets related to the gene therapy candidate ST-920 for a total potential consideration of $211 million.
🚩 Red Flags
- Active Chapter 11 bankruptcy proceedings (Case No. 26-10989).
- Delisted from Nasdaq; currently trading on OTCID Basic Market (SGMOQ).
- Asset sale via a court-supervised auction process, indicating significant distress.
- The APA contains no survival of representations and warranties or indemnification remedies for the buyer.
📋 Key Facts
- Company filed for voluntary Chapter 11 bankruptcy on June 23, 2026.
- Entered into an Asset Purchase Agreement (APA) with PTC Therapeutics, Inc. on August 25, 2026.
- The transaction involves the sale of assets related to ST-920 (isaralgagene civaparvovec) for Fabry disease.
- Total consideration includes $111,000,000 in cash at closing.
- Contingent milestone payments up to $100,000,000 ($80M for accelerated FDA approval; $20M for full FDA approval).
- The sale is subject to Bankruptcy Court approval, with a hearing scheduled for September 10, 2026.
- The company's common stock was suspended from Nasdaq on May 5, 2026, and currently trades on the OTCID Basic Market (SGMOQ).
Sangamo Therapeutics has successfully concluded a Section 363 auction process in its Chapter 11 bankruptcy case, selecting bids from PTC Therapeutics and Eli Lilly. The sale is expected to yield approximately $163.55 million in cash plus up to $100 million in milestone payments.
🚩 Red Flags
- Company is currently in Chapter 11 bankruptcy proceedings.
- Common stock was delisted from Nasdaq on May 5, 2026, and currently trades on the OTCID Basic Market (SGMOQ).
- Nasdaq Hearings Panel denied request to continue listing on July 14, 2026.
📋 Key Facts
- Company filed for Chapter 11 bankruptcy on June 23, 2026 (Case No. 26-10989).
- Auction process under Section 363 of the Bankruptcy Code has concluded.
- Winning bidders: PTC Therapeutics, Inc. and Eli Lilly and Company.
- Total cash consideration at closing: approximately $163.55 million.
- Potential future milestone payments: up to $100 million.
- The sale is subject to Bankruptcy Court approval and Hart-Scott-Rodino antitrust clearance.
Sangamo Therapeutics, Inc. has filed a monthly operating report (MOR) as part of its ongoing Chapter 11 bankruptcy proceedings. The company is currently delisted from Nasdaq and trading on the OTCID Basic Market under the symbol 'SGMOQ'.
🚩 Red Flags
- Active Chapter 11 bankruptcy proceedings.
- Delisted from Nasdaq and relegated to OTC markets.
- Trading in common stock is described as 'highly speculative' with substantial risk of zero recovery for holders.
- The company has failed to maintain its primary exchange listing.
📋 Key Facts
- Company filed for Chapter 11 relief in the U.S. Bankruptcy Court for the District of Delaware on June 23, 2026 (Case No. 26-10989).
- Nasdaq delisted the company's common stock; trading was suspended on May 5, 2026.
- The Nasdaq Hearings Panel denied the company's request to continue listing on July 14, 2026.
- Common stock is currently trading on the OTCID Basic Market under symbol 'SGMOQ'.
- This filing serves as a submission of the Monthly Operating Report (MOR) for the period June 1, 2026, to June 30, 2026.
Sangamo Therapeutics, Inc. reports that the Nasdaq Hearings Panel has denied its request to continue listing on the Nasdaq Capital Market, effectively finalizing its delisting. Additionally, the company is proceeding with a Chapter 11 bankruptcy sale process following court approval of bidding procedures.
🚩 Red Flags
- Bankruptcy filing (Chapter 11) confirmed
- Final delisting from Nasdaq confirmed; no intent to appeal further
- Trading moved to OTCID Basic Market ('SGMOQ')
- Asset sale process underway, indicating potential liquidation or significant restructuring
📋 Key Facts
- Nasdaq Hearings Panel issued a written determination on July 14, 2026, denying the request to continue listing.
- The Company's common stock was suspended from Nasdaq on May 5, 2026, and currently trades on the OTCID Basic Market under symbol 'SGMOQ'.
- Sangamo filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026 (Case No. 26-10989) in the District of Delaware.
- The Court approved Bidding Procedures via an order on July 14, 2026.
- Bid Deadline for company assets is set for August 4, 2026, at 5:00 p.m. ET.
- An auction of assets is scheduled for August 10, 2026, if multiple qualified bids are received.
- A Sale Hearing to seek Court approval for successful bids is scheduled for August 20, 2026.
- The Company does not intend to request a review of the Nasdaq Panel's decision.
Sangamo Therapeutics, Inc. has filed for voluntary Chapter 11 bankruptcy protection, resulting in its common stock moving to the OTCID Basic Market under symbol 'SGMOQ'. Additionally, the company terminated Ernst & Young LLP as its independent auditor following the bankruptcy filing.
🚩 Red Flags
- Chapter 11 Bankruptcy filing
- Delisting notice from Nasdaq (minimum bid price non-compliance)
- Auditor change following bankruptcy filing
- Stock moved to OTCID Basic Market (SGMOQ) indicating high risk of equity wipeout in restructuring
- Previous 'going concern' explanatory paragraphs in EY reports for FY2024 and FY2025
📋 Key Facts
- Company filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 26-10989).
- Common stock began trading on the OTCID Basic Market under symbol 'SGMOQ' on June 24, 2026.
- Ernst & Young LLP (EY) was terminated as the independent registered public accounting firm on June 25, 2026.
- Nasdaq delisting notice received April 28, 2026, due to failure to meet minimum bid price requirements; appeal is currently pending/stayed.
- Stock previously moved from Nasdaq to OTCQB Venture Market on May 5, 2026.
Sangamo Therapeutics, Inc. is filing an amendment to its 8-K to include asset purchase agreements with Eli Lilly and Company and Astellas Gene Therapies, Inc. The company is also currently delisted from Nasdaq and trading on the OTCQB due to minimum bid price non-compliance.
🚩 Red Flags
- Delisting notice from Nasdaq due to minimum bid price non-compliance.
- Trading suspension on major exchange (Nasdaq) and move to OTCQB market.
- Significant asset divestitures/transfers occurring amidst delisting (potential liquidity or restructuring event).
📋 Key Facts
- Received Nasdaq delisting notice on April 28, 2026, for failure to meet minimum bid price requirements.
- Common stock suspended from Nasdaq and began trading on OTCQB Venture Market on May 5, 2026.
- Executed an Asset Purchase Agreement dated June 22, 2026, with Eli Lilly and Company (via Merope Acquisition Sub, LLC) and Sangamo subsidiaries.
- Executed an Asset Purchase Agreement dated June 22, 2026, with Astellas Gene Therapies, Inc.
Sangamo Therapeutics, Inc. has filed for voluntary Chapter 11 bankruptcy protection in the District of Delaware to maximize stakeholder value through asset sales. The company is currently operating as a debtor-in-possession and has entered into two stalking horse asset purchase agreements with Eli Lilly and Astellas Pharma.
🚩 Red Flags
- Chapter 11 Bankruptcy filing (extreme risk of equity wipeout).
- Delisting from Nasdaq and transition to OTCQB market.
- Sale of 'all or substantially all assets' via stalking horse bids indicates a liquidation-style restructuring.
- Heavy reliance on DIP financing for post-petition operations.
📋 Key Facts
- Filed voluntary petition for Chapter 11 bankruptcy on June 23, 2026 (Case No. 26-10989).
- Entered into a 'Lilly Stalking Horse APA' with Eli Lilly for $50 million plus assumption of liabilities, covering technology platforms like AAV capsid engineering and zinc finger protein tech.
- Entered into an 'Astellas Stalking Horse APA' for the sale of isaralgagene civaparvovec assets for $25 million + up to $25 million in milestones.
- Secured a DIP Facility from Northridge ATM, LLC for up to $30 million in senior secured debt.
- Common stock was previously suspended from Nasdaq and began trading on the OTCQB Venture Market on May 5, 2026, due to failure to meet minimum bid price requirements.
Sangamo Therapeutics reported Q1 2026 financial results and disclosed that its common stock was suspended from Nasdaq and moved to the OTCQB Venture Market on May 5, 2026. The delisting resulted from a failure to meet Nasdaq's minimum bid price requirement, and while an appeal is pending, the trading suspension remains in effect.
🚩 Red Flags
- Involuntary delisting from a major exchange (Nasdaq).
- Transition to the OTCQB Venture Market, which typically involves lower liquidity and less institutional oversight.
- Failure to maintain the $1.00 minimum bid price requirement.
- Trading suspension on Nasdaq is already in effect as of May 5, 2026.
📋 Key Facts
- Received Nasdaq delisting notice on April 28, 2026, due to minimum bid price non-compliance.
- Common stock was suspended from Nasdaq and began trading on the OTCQB Venture Market on May 5, 2026.
- The Company has requested a hearing before a Nasdaq Hearings Panel to appeal the delisting.
- The appeal stays the formal delisting process but does not stay the current trading suspension on Nasdaq.
- Financial results for the quarter ended March 31, 2026, were released concurrently on May 14, 2026.
Sangamo Therapeutics received a formal delisting notice from Nasdaq on April 28, 2026, after failing to regain compliance with the $1.00 minimum bid price requirement. Trading on the Nasdaq Capital Market will be suspended on May 5, 2026, and the company's common stock is expected to transition to the OTCQB Venture Market.
🚩 Red Flags
- Formal delisting determination from a major national exchange (Nasdaq).
- Failure to regain compliance after two 180-day grace periods (totaling approximately one year).
- Immediate trading suspension scheduled for May 5, 2026.
- Transition to the OTCQB Venture Market, which typically involves lower liquidity and reduced institutional interest.
📋 Key Facts
- The Company received a written delisting notice from Nasdaq on April 28, 2026.
- The delisting is due to the stock price remaining below the $1.00 minimum bid price requirement for over 360 days.
- Trading on Nasdaq will be suspended at the open of trading on May 5, 2026.
- Sangamo plans to appeal the decision to a Nasdaq Hearings Panel, but the appeal will not stay the trading suspension.
- The Company has received approval to quote its common stock on the OTCQB Venture Market starting May 5, 2026, under the symbol 'SGMO'.
Sangamo Therapeutics announced its financial results for the fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The company is listed on the Nasdaq Capital Market under the ticker SGMO.
Sangamo Therapeutics announced a $25 million underwritten offering of common stock and warrants at a significant discount to previous warrant exercise prices. The deal includes a warrant amendment that reprices existing warrants from $1.00 down to $0.4719.
🚩 Red Flags
- Significant dilution: Issuance of over 35 million new shares plus millions in warrants.
- Deeply discounted pricing: The offering price ($0.4719) is significantly lower than previous warrant exercise prices ($1.00).
- Warrant Repricing: Existing holders are being compensated with a massive reduction in exercise price, which typically signals distressed financing terms or significant downward pressure on share price.
📋 Key Facts
- Offering size: Approximately $25.0 million in gross proceeds.
- Securities offered: 35,190,292 shares of common stock and 17,787,033 pre-funded warrants.
- Combined offering price (Stock + Purchase Warrant): $0.4719 per share/warrant unit.
- Pre-funded warrant exercise price: $0.01 per share.
- Warrant Amendment: Repriced 23,809,523 existing warrants from an exercise price of $1.00 to $0.4719.
- Underwriters: Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC.
Sangamo Therapeutics announced clinical data from its Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The data showed positive eGFR slope trends and sustained alpha-galactosidase A activity, supporting the company's ongoing BLA submission under the FDA's Accelerated Approval Program.
🚩 Red Flags
- One treatment-related serious adverse event (SAE) reported (shoulder enthesopathy).
- Potential for immunogenicity issues, though data showed a decrease in neutralizing antibodies in 80% of patients.
📋 Key Facts
- Phase 1/2 STAAR study is complete; all 32 patients with 52 weeks follow-up have rolled into a long-term follow-up study.
- FDA has agreed that Phase 1/2 data can serve as the primary basis for Accelerated Approval using mean annualized eGFR slope at 52 weeks.
- Sangamo initiated a rolling BLA submission to the FDA in December 2025.
- Data cutoff date was April 10, 2025; analysis included 33 patients (9 dose escalation, 24 dose expansion).
- Clinical results showed positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year at 52 weeks.
- All 18 patients on Enzyme Replacement Therapy (ERT) were able to safely withdraw from ERT following dosing; one patient has been off ERT for >4 years.
- Safety profile: Most AEs were Grade 1 or 2. One serious adverse event (shoulder enthesopathy) was deemed treatment-related.
Sangamo Therapeutics announced the termination of its Principal Financial Officer, Prathyusha Duraibabu, effective February 3, 2026. Nikunj Jain has been appointed as Interim CFO to fill the vacancy.
🚩 Red Flags
- Sudden departure of the Principal Financial Officer (PFO).
- Low cash position ($20.9M) relative to typical biotech burn rates, though preliminary.
- Appointment of an 'Interim' CFO often suggests a period of transition or instability in finance leadership.
📋 Key Facts
- Prathyusha Duraibabu (Principal Financial Officer) terminated employment on February 2, 2026.
- Nikunj Jain (VP, Finance and Corporate Controller) appointed as Interim Chief Financial Officer effective February 3, 2026.
- Preliminary cash and cash equivalents as of December 31, 2025, were approximately $20.9 million.
- Interim CFO Nikunj Jain will not receive additional compensation for the new role.
Sangamo Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 6, 2025.
Sangamo Therapeutics, Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. The company must maintain a closing bid price of at least $1.00 for 10 consecutive trading days by April 27, 2026, to avoid delisting.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq minimum bid price rule.
- Failure to regain compliance within the initial 180-day window (original deadline was Oct 27, 2025).
- Risk of delisting if the $1.00 threshold is not met by April 27, 2026.
📋 Key Facts
- Received an Extension Notice from Nasdaq on October 29, 2025.
- The extension provides until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Compliance is achieved if the stock closes at or above $1.00 for 10 consecutive trading days.
- The company previously failed to meet the requirement by the original deadline of October 27, 2025.
Sangamo Therapeutics announced the resignation of CFO Prathyusha Duraibabu, effective October 1, 2025. She will transition to a part-time role as Principal Financial Officer, while Nikunj Jain has been appointed as the new Principal Accounting Officer.
🚩 Red Flags
- CFO transition from full-time to part-time role can sometimes indicate internal friction or instability in financial leadership.
- The use of a retention bonus for the departing CFO suggests an effort to ensure continuity during a period of leadership change.
📋 Key Facts
- CFO Prathyusha Duraibabu is resigning from her full-time position effective October 1, 2025.
- Ms. Duraibabu will transition to part-time employment with an annual base salary of $145,188.
- A cash retention bonus of $160,000 is scheduled for Ms. Duraibabu on January 31, 2026, contingent upon continued employment.
- Nikunj Jain (VP, Finance and Corporate Controller) appointed as Principal Accounting Officer effective October 1, 2025.
- Mr. Jain's new compensation includes an annual base salary of $347,548 and a target cash bonus of 30%.
Sangamo Therapeutics, Inc. announced the resignation of its Chief Financial Officer, Prathyusha Duraibabu, effective October 1, 2025. The departure is for a new role at a private AI company and does not involve disagreements with the company's operations or financials.
🚩 Red Flags
- Sudden departure of a CFO can sometimes signal underlying issues, though the filing explicitly denies any disagreement with financials or internal controls.
📋 Key Facts
- Prathyusha Duraibabu resigned as CFO on September 9, 2025.
- Effective date of resignation: October 1, 2025.
- The departure is for a senior leadership role at a privately-held AI company.
- Ms. Duraibabu will transition to part-time employment and serve as interim principal financial officer pending a permanent successor.
- The Company explicitly stated the resignation is not due to disagreements regarding operations, financial statements, internal controls, auditors, or policies.
Sangamo Therapeutics announced updated Phase 1/2 clinical data for its gene therapy candidate, ST-920 (isaralgagene civaparvovec), for Fabry disease. The data showed positive eGFR slopes and significant improvements in quality of life scores, supporting the company's plan to submit a BLA as early as Q1 2026.
🚩 Red Flags
- Funding dependency: BLA submission is explicitly subject to 'its ability to secure adequate additional funding'.
- Safety note: 7 treatment-emergent serious adverse events (TESAEs) were reported in five patients, including sepsis and cerebrovascular accident.
📋 Key Facts
- Updated clinical data from Phase 1/2 STAAR study presented at ICIEM2025 on September 4, 2025.
- Data cutoff date was April 10, 2025; 33 patients were treated in total (9 dose escalation, 24 expansion).
- Mean annualized eGFR slope at 52 weeks was +1.965 mL/min/1.73m2/year across all 32 dosed patients.
- Significant improvements reported in SF-36 Quality of Life scores and GI symptom rating scales (GSRS).
- Company intends to submit a Biologics License Application (BLA) for ST-920 as early as Q1 2026, contingent on securing adequate funding.
- The FDA has previously agreed that this study data can serve as the basis for Accelerated Approval.
Sangamo Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended June 30, 2025.
- Filing date: August 7, 2025.
Sangamo Therapeutics announced positive topline results from its Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The data supports the company's plan to submit a Biologics Licensing Application (BLA) via the FDA's Accelerated Approval pathway as early as Q1 2026.
🚩 Red Flags
- Forward-looking statements explicitly mention the 'need for substantial additional funding' to continue operating as a going concern.
- Potential risk regarding the durability of therapeutic effects in patients over longer periods.
📋 Key Facts
- Positive mean annualized eGFR slope of 1.965 mL/min/1.73m² at 52-weeks across 32 patients.
- FDA has agreed that the eGFR slope will serve as an intermediate clinical endpoint for Accelerated Approval.
- Long-term follow-up (104-weeks) showed a mean annualized eGFR slope of 1.747 mL/min/1.73m² in 19 patients.
- All 18 patients who started on enzyme replacement therapy (ERT) have successfully withdrawn from ERT and remain off it.
- The study demonstrated statistically significant improvements in quality of life scores (SF-36) and gastrointestinal symptoms (GSRS).
- Safety profile was favorable; most adverse events were Grade 1-2, with no safety-related discontinuations.
Sangamo Therapeutics, Inc. reported the results of its annual meeting of stockholders held on June 12, 2025. Stockholders approved an amendment to the 2018 Equity Incentive Plan and ratified the appointment of Ernst & Young LLP as the independent auditor.
🚩 Red Flags
- Significant dilution potential due to the increase of 14 million common shares and 28 million option-related shares under the Amended 2018 Plan.
📋 Key Facts
- Stockholders approved an increase in the aggregate number of shares under the 2018 Equity Incentive Plan by 14,000,000 shares.
- The total maximum number of shares issuable under incentive stock options in the Amended 2018 Plan is now 123,200,000 shares.
- All nine nominees for the Board of Directors were elected to serve until the 2026 annual meeting.
- Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025 was approved with significant majority (119.6M 'For' vs 12M 'Against').
- The advisory vote on executive compensation received 32,804,256 votes in favor.
Sangamo Therapeutics entered into an underwriting agreement to conduct a significant equity offering consisting of common stock and warrants. The offering is expected to raise approximately $23.0 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the large number of warrants (totaling over 81 million shares via Pre-Funded and Purchase Warrants).
- Deeply discounted offering price ($0.50/share) relative to typical market valuations for biotech companies in development stages.
- The use of 'Pre-Funded Warrants' often indicates a need for immediate capital where the company is struggling to find traditional equity investors at higher prices.
📋 Key Facts
- Issuance of 12,235,000 shares of Common Stock at $0.50 per share (combined with Purchase Warrant).
- Issuance of Pre-Funded Warrants to purchase 34,398,393 shares of Common Stock.
- Issuance of Purchase Warrants for 46,633,393 shares of Common Stock at an exercise price of $0.75.
- Expected gross proceeds: approximately $23.0 million.
- Anticipated closing date: May 14, 2025.
- Underwriter: Cantor Fitzgerald & Co.
Sangamo Therapeutics received a deficiency notice from Nasdaq because its common stock bid price closed below $1.00 for 30 consecutive business days. The company has until October 27, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum bid price requirement).
- Potential for a mandatory reverse stock split to regain compliance.
- Risk of delisting if the $1.00 threshold is not maintained.
📋 Key Facts
- Received deficiency notice on April 30, 2025, regarding Nasdaq Listing Rule 5550(a)(2).
- The bid price has closed below $1.00 for the last 30 consecutive business days.
- Compliance deadline (Compliance Date) is October 27, 2025.
- To regain compliance, the stock must maintain a minimum closing bid price of at least $1.00 for 10 consecutive business days before the Compliance Date.
- A second 180-day compliance period may be available if the company meets other listing standards and intends to cure via a reverse stock split.
Sangamo Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the release of their annual earnings data.
📋 Key Facts
- Report date: March 17, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Information under Item 2.02 is furnished and not 'filed' for purposes of Section 18 liability.
Sangamo Therapeutics announced updated preliminary Phase 1/2 clinical data for its gene therapy candidate, isaralgagene civaparvovec (ST-920), for the treatment of Fabry disease. The data shows sustained alpha-galactosidase A activity and potential improvements in kidney function and quality of life in treated patients.
🚩 Red Flags
- Risk noted regarding the lack of capital resources to obtain regulatory approval and commercialize products.
- Serious adverse events (SAEs) reported in four patients: left arm pain, non-cardiac chest pain, sepsis, stroke, and shoulder enthesopathy.
📋 Key Facts
- Phase 1/2 STAAR study enrollment and dosing are complete; 33 patients were treated as of the September 12, 2024 cutoff.
- FDA has provided a clear regulatory pathway for Accelerated Approval using eGFR slope at 52 weeks as an intermediate endpoint.
- Potential Biologics License Application (BLA) submission is anticipated in the second half of 2025.
- Data showed sustained elevated alpha-galactosidase A activity up to 42 months in some patients.
- In patients with ≥12 months follow-up, a mean annualized eGFR slope of 3.061 mL/min/1.73m²/year was observed.
- Statistically significant improvements were reported in SF-36 Quality of Life scores and gastrointestinal symptoms.
- The company is actively pursuing business development discussions for a potential ST-920 collaboration agreement.
Pfizer Inc. has notified Sangamo Therapeutics of its decision to terminate their collaboration agreement for the hemophilia A gene therapy candidate, giroctocogene fitelparvovec (SB-525), effective April 21, 2025. Pfizer is opting not to pursue regulatory filings or commercialization for this product.
🚩 Red Flags
- Loss of a major blue-chip partner (Pfizer) for a lead candidate
- Significant loss of future revenue streams, including potential royalties (14%-20%) and high-value milestones (up to $395M combined)
- Increased operational burden as Sangamo must now fund/manage the transition and seek new partners for regulatory approval and commercialization
- Forward-looking statements explicitly mention risks regarding 'inability to secure options to bring the program forward' and 'lack of resources to fully develop' products.
📋 Key Facts
- Termination date: April 21, 2025
- Reason for termination: Pfizer's decision not to submit a BLA/MAA or pursue commercialization of SB-525
- Sangamo will regain exclusive, worldwide, sublicensable rights to use Pfizer's relevant IP to continue development and commercialization
- Pfizer will transition the SB-525 program back to Sangamo at Sangamo's request and expense
- Pfizer is entitled to low single-digit royalties on net sales if Sangamo continues development
- Sangamo previously received $70M upfront and $55M in milestone payments from Pfizer
Sangamo Therapeutics resolved a legal uncertainty regarding the validity of its share increase amendment following a favorable Delaware Court of Chancery opinion. Additionally, the company highlighted Phase 3 clinical data from its co-developed gene therapy with Pfizer.
🚩 Red Flags
- Prior legal uncertainty regarding the validity of authorized share increases due to a stockholder class action lawsuit.
📋 Key Facts
- Delaware Court of Chancery issued an opinion on November 27, 2024, confirming Sangamo's Proxy Statement accurately described voting requirements for a share increase amendment.
- The Common Stock Increase Amendment increased authorized shares from 640,000,000 to 960,000,000 shares.
- Sangamo dismissed its Section 205 Application in the Court of Chancery on December 6, 2024, following the court's opinion.
- Pfizer presented Phase 3 AFFINE trial data for giroctocogene fitelparvovec (co-developed with Sangamo) at the American Society of Hematology Annual Meeting.
Sangamo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 12, 2024.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 12, 2024.
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Sangamo Therapeutics is notifying stockholders of a scheduled Court of Chancery hearing on December 12, 2024, to validate a recent increase in authorized common stock. This legal action follows a stockholder class action lawsuit challenging the validity of the share increase due to differing interpretations of voting thresholds under Delaware law.
🚩 Red Flags
- Legal uncertainty regarding the validity of authorized shares could impact future equity issuances and capital raising capabilities.
- Active stockholder class action litigation against the company and its board of directors.
📋 Key Facts
- The company increased authorized Common Stock from 640,000,000 to 960,000,000 shares via a Certificate of Amendment on June 4, 2024.
- A stockholder class action lawsuit was filed in the Delaware Court of Chancery on June 3, 2024, alleging the share increase was invalidly authorized.
- The dispute centers on whether a 'majority-of-votes-cast' or 'majority-of-outstanding-shares' standard was required under DGCL Section 242(d)(2).
- The Company filed a Section 205 application to ratify and validate the potentially defective corporate act.
- A final hearing is scheduled for December 12, 2024, at 9:15 a.m. ET in Wilmington, Delaware.
Sangamo Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 6, 2024.
Sangamo Therapeutics reported positive topline results from the Phase 3 AFFINE clinical trial for giroctocogene fitelparvovec, a gene therapy candidate being developed in partnership with Pfizer. The trial evaluates the treatment of adults with moderately severe to severe hemophilia A.
📋 Key Facts
- Positive topline results reported from the registrational Phase 3 AFFINE clinical trial.
- The product under evaluation is giroctocogene fitelparvovec, an investigational gene therapy.
- The clinical trial is being conducted by Pfizer, Inc. for Sangamo's candidate.
- Target indication: adults with moderately severe to severe hemophilia A.
Sangamo Therapeutics announced the results of its annual meeting where stockholders approved significant increases to authorized share counts and equity incentive plans. These actions provide the company with increased flexibility for future capital raises and employee compensation.
🚩 Red Flags
- Significant increase in authorized shares (from 640M to 960M) often precedes potential dilutive equity offerings or warrants exercises.
📋 Key Facts
- Stockholders approved an amendment to increase total authorized common stock from 640,000,000 to 960,000,000 shares.
- The 2018 Equity Incentive Plan was amended to increase the aggregate number of shares by 11,000,000 and incentive stock options by 22,000,000 (totaling 95,200,000 shares).
- The nine nominees for the Board of Directors were elected at the annual meeting held on June 4, 2024.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
Sangamo Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- The filing is a routine announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Filing date: May 9, 2024.
Sangamo Therapeutics received a deficiency notice from Nasdaq because its common stock bid price closed below $1.00 for 30 consecutive business days. The company has until October 21, 2024, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice received (Nasdaq Rule 5450(a)(1))
- Stock price has been below $1.00 for 30 consecutive business days
- Potential requirement for a reverse stock split to maintain listing
📋 Key Facts
- Received deficiency notice on April 24, 2024.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding minimum $1.00 bid price.
- Compliance deadline (Compliance Date) is October 21, 2024.
- Must maintain a minimum closing bid price of at least $1.00 for 10 consecutive business days to regain compliance.
- A second 180-day compliance period may be available if the company transfers to Nasdaq Capital Market and potentially effects a reverse stock split.
Sangamo Therapeutics announced a registered direct offering of common stock and warrants to institutional investors. The offering aims to raise approximately $24 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the large number of warrants (over 32 million total shares via warrants/pre-funded warrants).
- Low offering price ($0.84) relative to typical micro-cap valuations, suggesting urgent need for capital.
- Warrants are exercisable in six months, creating a potential 'overhang' on the stock price.
📋 Key Facts
- Offering size: 24,761,905 shares of common stock and pre-funded warrants for up to 3,809,523 shares.
- Accompanying purchase warrants for up to 28,571,428 shares.
- Combined offering price (stock + warrant): $0.84 per share/warrant unit.
- Pre-funded warrant exercise price: $0.01 per share.
- Purchase warrant exercise price: $1.00 per share, exercisable six months after issuance.
- Expected gross proceeds: ~$24.0 million (before fees).
- Placement agents: Barclays Capital Inc. and Cantor Fitzgerald & Co. with a 6% cash fee.
Sangamo Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of annual financial results (Item 2.02).
- The reporting period covered is the year ended December 31, 2023.
- Financial results were released via press release on March 13, 2024.
Sangamo Therapeutics announced updated preliminary Phase 1/2 clinical data for its gene therapy candidate ST-920 (isaralgagene civaparvovec) for Fabry disease. The data shows sustained alpha-galactosidase A activity and potential clinical benefits, though the company noted it is deferring further investment in registrational trials until a partnership or financing is secured.
🚩 Red Flags
- Financial constraint: Company explicitly stated it is 'deferring additional investments' in clinical trial planning pending external financing or partnership.
- Serious Adverse Events (SAEs) reported, including sepsis and stroke/ischemic stroke.
📋 Key Facts
- Phase 1/2 STAAR study evaluated ST-920 in 24 patients as of September 19, 2023 cutoff; total 28 patients dosed to date.
- Sustained, elevated expression of alpha-galactosidase A (α-Gal A) activity was observed in all nine dose escalation phase patients for nearly three years in the longest-treated patient.
- 11 out of 12 patients who were previously on Enzyme Replacement Therapy (ERT) successfully remained off ERT with sustained α-Gal A levels.
- Clinical improvements noted at 12-month follow-up: 69% of patients improved total Mainz Severity Score Index (MSSI); statistically significant improvements in Quality of Life (SF-36) and gastrointestinal symptoms (GSRS).
- Safety profile: Most adverse events were Grade 1 or 2; four serious adverse events (SAEs) reported including sepsis, stroke/ischemic stroke, and enthesopathy.
- Company is deferring additional investments in planning for a potential registrational trial until a collaboration partnership or trial financing is secured.
Sangamo Therapeutics announced that the Board will not award annual cash bonuses to executive officers for 2023 performance. Simultaneously, the company has implemented a retention program for US and UK employees, specifically targeting key executives with milestone-based cash payments tied to successful capital raising or change of control events.
🚩 Red Flags
- Explicit mention that the company is seeking to 'raise additional capital in support of its operations,' indicating liquidity constraints.
- Incentives are tied specifically to 'increases in cash resources' and 'change of control,' suggesting a high-pressure need for financing or an exit strategy.
- Elimination of annual performance bonuses often signals cost-cutting measures due to financial distress.
📋 Key Facts
- Board determined not to award annual cash bonuses for 2023 company performance to executive officers.
- Dr. Sandy Macrae (CEO) and Prathyusha Duraibabu (CFO) are excluded from the standard bonus but eligible for retention payments.
- Retention Program targets US and UK employees to support near-term retention.
- Retention Payments for CEO: up to $429,820; CFO: up to $193,584.
- Milestones for retention payments include increasing cash resources via capital raising/business development or a change of control before the end of 2024.